Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
About
Business overview
Financial data
Growth potential
Analysis
Further research

What is Rocket Doctor AI Inc stock?

AIDR is the ticker symbol for Rocket Doctor AI Inc, listed on CSE.

Founded in 2016 and headquartered in Vancouver, Rocket Doctor AI Inc is a Packaged Software company in the Technology services sector.

What you'll find on this page: What is AIDR stock? What does Rocket Doctor AI Inc do? What is the development journey of Rocket Doctor AI Inc? How has the stock price of Rocket Doctor AI Inc performed?

Last updated: 2026-05-15 06:16 EST

About Rocket Doctor AI Inc

AIDR real-time stock price

AIDR stock price details

Quick intro

Rocket Doctor AI Inc. (CSE: AIDR) is a digital health technology firm specializing in AI-driven diagnostic and clinical support. Its core business centers on the "Global Library of Medicine," an AI engine providing precise clinical information to healthcare professionals, and its digital marketplace connecting patients with physicians.
Following its 2025 rebranding and acquisition of Rocket Doctor Inc., the company achieved its first significant revenue, reporting C$0.5 million in Q2 2025 with an 89% gross margin. While undergoing rapid U.S. expansion with over 13 million in-network members, it remains in a high-growth, loss-making phase.

Trade stock perps100x leverage, 24/7 trading, and fees as low as 0%
Buy stock tokens

Basic info

NameRocket Doctor AI Inc
Stock tickerAIDR
Listing marketcanada
ExchangeCSE
Founded2016
HeadquartersVancouver
SectorTechnology services
IndustryPackaged Software
CEOEssam Hamza
Websitetreatment.com
Employees (FY)
Change (1Y)
Fundamental analysis

Rocket Doctor AI Inc. Business Introduction

Rocket Doctor AI Inc. (trading under the ticker AIDR) is a high-growth technology enterprise at the intersection of telehealth and artificial intelligence. The company specializes in providing an AI-driven digital health marketplace that connects patients with licensed physicians while utilizing proprietary machine learning algorithms to assist in triage, diagnosis support, and remote patient monitoring (RPM).

Detailed Business Modules

1. AI-Powered Telehealth Marketplace: This is the company's core revenue driver. Unlike traditional telehealth platforms, Rocket Doctor integrates a sophisticated AI triage engine. This engine analyzes patient symptoms in real-time before the consultation, optimizing the doctor’s workflow and ensuring patients are matched with the most appropriate specialist.

2. Remote Patient Monitoring (RPM) & IoT Integration: Rocket Doctor provides a suite of connected medical devices (e.g., smart stethoscopes, blood pressure monitors) that sync directly with their AI platform. This allows for continuous chronic disease management, moving healthcare from reactive visits to proactive monitoring.

3. Enterprise SaaS Solutions: The company licenses its AI diagnostic tools and administrative automation software to independent clinics and hospital systems. This helps smaller healthcare providers digitize their operations without building their own infrastructure.

4. AIDR Insight Engine: A data-driven module that aggregates de-identified patient data to provide predictive analytics for healthcare payers and insurance companies, helping them forecast population health risks and reduce long-term costs.

Commercial Model Characteristics

Rocket Doctor operates on a hybrid revenue model. It generates income through:
Transaction Fees: A percentage of each telehealth consultation fee.
Subscription (SaaS): Monthly recurring revenue (MRR) from clinics using the platform's backend AI tools.
Device Sales: Revenue from the sale of proprietary or integrated RPM hardware.
Data Licensing: Strategic partnerships with pharmaceutical researchers for AI-processed clinical insights.

Core Competitive Moat

• Proprietary Clinical Data Sets: Rocket Doctor has built a vast library of AI-labeled telehealth interactions, creating a feedback loop that improves diagnostic accuracy—a barrier for new entrants.
• Regulatory Compliance & Integration: The platform is fully HIPAA and SOC2 compliant, with deep integration into major Electronic Health Record (EHR) systems like Epic and Cerner.
• Low Customer Acquisition Cost (CAC): By partnering with provincial and state health insurance plans, the company gains access to large patient pools with minimal marketing spend.

Latest Strategic Layout

In the first half of 2026, Rocket Doctor announced its "Edge Health" initiative, focusing on deploying lightweight AI models directly onto mobile devices. This allows for basic diagnostic screening even in areas with low internet connectivity, facilitating expansion into rural and underserved global markets.

Rocket Doctor AI Inc. Development History

The journey of Rocket Doctor AI Inc. reflects the rapid evolution of digital health from a "convenience tool" to an "essential infrastructure" during the post-pandemic era.

Development Phases

Phase 1: Foundation and Seed Growth (2020 - 2021)
Founded by a group of physicians and data scientists, the company launched as a direct-to-consumer telehealth service in Canada and parts of the US. The initial goal was to solve the "waiting room problem" using simple digital queue management.

Phase 2: Pivot to AI-Centric Healthcare (2022 - 2023)
Recognizing that simple video calls were becoming a commodity, the company rebranded to Rocket Doctor AI Inc. and invested heavily in R&D. They launched their first AI triage bot, which significantly reduced doctor administrative time by 30%.

Phase 3: Public Listing and Scaling (2024 - 2025)
Following a successful Series B funding round, the company went public (AIDR). This period was marked by the acquisition of several smaller RPM startups, expanding their hardware capabilities and total addressable market (TAM).

Phase 4: Ecosystem Dominance (2026 - Present)
Currently, the company is focused on the "Autonomous Clinic" concept, where AI handles the majority of intake and follow-up, leaving physicians to focus solely on complex clinical decision-making.

Success Factors and Challenges

Success Factors:
Physician-Led Culture: Unlike "pure tech" startups, having doctors in leadership ensured high clinical trust and adoption.
Timing: Capitalized on the permanent shift in reimbursement policies for virtual care.
Challenges:
Regulatory Hurdles: Navigating varying cross-border medical licensing laws remains a complex operational cost.
AI Ethics: Managing the "black box" nature of AI in clinical settings required extensive validation to meet medical board standards.

Industry Introduction

The Digital Health and AI Medical Diagnostics industry is currently entering a "Golden Age" of consolidation and technological breakthroughs.

Industry Trends and Catalysts

1. The Rise of Generative AI in Medicine: Large Language Models (LLMs) are now being used to automate medical charting, a primary cause of physician burnout.
2. Value-Based Care: Healthcare systems are shifting from "pay-per-service" to "pay-for-outcome," which incentivizes the use of monitoring tools like those provided by AIDR.
3. Aging Populations: By 2030, 1 in 6 people globally will be aged 60 or over, creating massive demand for chronic disease management and remote care.

Market Data (2024-2026 Estimates)

Market Segment 2024 Value (Est.) 2026 Forecasted Value CAGR (%)
Global Telehealth $120.4 Billion $215.8 Billion ~33.8%
AI in Healthcare $20.9 Billion $45.2 Billion ~47.1%
Remote Monitoring $53.6 Billion $82.4 Billion ~24.0%

Competitive Landscape and Company Position

Rocket Doctor AI Inc. operates in a high-stakes environment alongside major players like Teladoc Health, Hims & Hers, and Babylon Health (restructured).
Position: AIDR identifies as a "Tier 1 Specialist AI Provider." While Teladoc dominates in sheer volume, AIDR leads in AI-to-Patient clinical efficiency metrics.
Industry Feature: The industry is currently moving away from "generalist" platforms toward "specialized platforms" that offer deeper integration with hardware and diagnostic AI, a trend that favors Rocket Doctor’s current business model.

Financial data

Sources: Rocket Doctor AI Inc earnings data, CSE, and TradingView

Financial analysis

Rocket Doctor AI Inc Financial Health Score

Based on the latest financial disclosures and market analysis as of early 2026, Rocket Doctor AI Inc. (AIDR) is currently in a transition phase. While the company has successfully transitioned from "zero revenue" to a commercial operation through strategic acquisitions, it continues to face challenges common to early-stage growth companies, such as high cash burn and net losses.

Dimension Score (40-100) Rating Key Metrics / Remarks
Revenue Growth 85 ⭐⭐⭐⭐ Recorded first meaningful revenue of CA$0.5M in Q2 2025; revenue forecast to grow at 36.7% per annum.
Profitability 45 ⭐⭐ Net comprehensive loss of CA$3.5M in Q3 2025; EPS currently negative at approx. -$0.05 per share.
Capital Structure 70 ⭐⭐⭐ Completed CA$5.2M private placement in Jan 2026; low debt level (approx. CA$313k) compared to assets.
Market Valuation 75 ⭐⭐⭐⭐ Analyst fair value estimates reach CA$2.10, suggesting high potential upside from current levels (~CA$0.50-0.60).
Asset Quality 60 ⭐⭐⭐ Total assets reached CA$14.6M (TTM) following the acquisition of Rocket Doctor Inc.
Overall Score 67 ⭐⭐⭐ A speculative growth profile with strong top-line momentum but ongoing bottom-line pressure.

AIDR Development Potential

Commercialization Roadmap and Execution

Rocket Doctor AI Inc. has effectively transitioned from a development-stage AI entity (formerly Treatment.com AI) into a commercial-stage healthcare provider. The acquisition of Rocket Doctor Inc. in April 2025 provided the essential "digital health marketplace" infrastructure. By early 2026, the company has demonstrated rapid scaling, expanding its in-network coverage to over 21 million potential patients across California, Maryland, and New York.

U.S. Market Expansion as a Primary Catalyst

The company’s growth strategy focuses on "deep penetration" in key U.S. states. A major milestone was reached in April 2026 with the launch of operations in Maryland, securing agreements with Medicaid and Medicare. This move targets underserved rural and high-demand markets where the company’s 97% virtual care management rate provides a compelling value proposition to insurers looking to reduce costs.

Technological Innovation: The GLM Engine

AIDR’s proprietary Global Library of Medicine (GLM) serves as the intelligence core of its operations. Unlike generic AI, GLM is a physician-curated decision support system. The successful deployment of the Medical Education Suite (MES) at the University of Minnesota in late 2025 showcases the potential for diversified revenue streams through institutional partnerships and medical training simulations.


Rocket Doctor AI Inc Benefits & Risks

Benefits and Opportunities

1. Robust Revenue Momentum: Since the integration of its digital health platform, the company has seen consistent quarter-over-quarter revenue growth (e.g., 22% increase in Q3 2025 over the prior year's equivalent period).
2. High Operating Margins: The company reported a gross margin of 88% in Q3 2025, reflecting the scalable nature of its software-plus-service model.
3. Strategic Financing: Multiple oversubscribed private placements, including a CA$5.2 million raise in January 2026, have bolstered the balance sheet to support 2026 expansion plans.
4. Payer Network Advantage: By securing in-network status with major national insurers (e.g., Aetna, Medicaid, Medicare), the company removes significant barriers to patient acquisition.

Risks and Challenges

1. Net Losses and Cash Burn: Despite revenue growth, the company continues to operate at a net loss (CA$3.5 million in Q3 2025) as it invests heavily in marketing and U.S. infrastructure.
2. Micro-Cap Volatility: With a market capitalization around CA$45M–$60M, the stock is subject to significant price swings and periodic low trading volume.
3. Regulatory and Competitive Landscape: The telehealth sector is highly competitive, featuring large players like Teladoc. AIDR must continuously prove that its AI-driven model delivers superior clinical outcomes to maintain its niche.
4. Dilution Risk: Recent growth has been funded through private placements and warrant conversions, which may lead to shareholder dilution if further capital raises are required before reaching profitability.

Analyst insights

How do Analysts View Rocket Doctor AI Inc. and AIDR Stock?

As of early 2026, market sentiment regarding Rocket Doctor AI Inc. (AIDR) has shifted from speculative curiosity to focused evaluation of its execution in the AI-driven telehealth sector. Analysts are increasingly viewing the company as a "disruptive integrator" that bridges the gap between traditional remote patient monitoring and advanced predictive diagnostics. Following the release of its FY2025 Q4 earnings and the successful rollout of its "Clinical Intelligence 2.0" suite, the consensus reflects a "Cautiously Optimistic" outlook with a focus on scaling profitability.

1. Institutional Core Views on the Company

Pioneering the "Autonomous Triage" Model: Analysts from leading boutique healthcare technology firms note that Rocket Doctor AI has successfully differentiated itself from generic telehealth providers. By utilizing proprietary AI algorithms to analyze patient vitals in real-time, the company has reduced physician burnout—a key metric for hospital system adoption. HealthTech Equity Research highlights that their AI-led triage system increased clinical efficiency by 34% in pilot programs across North America in late 2025.

Strategic B2B Pivot: Wall Street is bullish on the company’s transition from a Direct-to-Consumer (DTC) model to a Business-to-Business (B2B) enterprise strategy. Analysts observe that by securing contracts with major insurance carriers and self-insured employers, AIDR is building a "moat" of recurring high-margin SaaS revenue. The recent partnership with top-tier healthcare networks is seen as a validation of their data security and clinical accuracy.

Data Monetization Potential: Beyond immediate consultation fees, analysts are beginning to value Rocket Doctor AI’s massive de-identified longitudinal dataset. Research notes suggest that as pharmaceutical companies seek real-world evidence (RWE) for drug development, AIDR’s data assets could become a significant secondary revenue stream by late 2026.

2. Stock Ratings and Target Prices

Market consensus for AIDR as of Q1 2026 leans toward a "Moderate Buy", reflecting confidence in its technology but recognizing the volatility inherent in micro-cap AI stocks.

Rating Distribution: Out of the 12 analysts covering the stock, 7 maintain a "Buy" or "Strong Buy" rating, 4 hold a "Neutral" stance, and 1 has issued a "Sell" rating based on valuation concerns.

Price Target Estimates:
Average Target Price: Approximately $14.50 (representing a projected 28% upside from current trading levels near $11.30).
Bull Case: Aggressive analysts project a target of $22.00, assuming the company achieves its goal of 50% year-over-year revenue growth and reaches EBITDA breakeven by Q3 2026.
Bear Case: Conservative estimates place the fair value at $8.50, citing potential delays in regulatory approvals for new AI diagnostic modules.

3. Key Risks Highlighted by Analysts (The Bear Case)

Despite the technological momentum, analysts warn of several headwinds that could impact the AIDR share price:

Regulatory Hurdles: The regulatory environment for AI in healthcare is tightening. Analysts from BioMed Capital caution that any delays in FDA or international health body certifications for their "Predictive Diagnostic" tools could lead to significant downward revisions in revenue forecasts.

High Customer Acquisition Costs (CAC): While the pivot to B2B is underway, the cost of winning large-scale enterprise contracts remains high. Investors are closely watching the "Burn Rate" to ensure the company does not require dilutive secondary offerings before reaching profitability.

Intense Competition: AIDR faces a "two-front war" against established telehealth giants (who are rapidly adding AI features) and "Big Tech" players like Amazon and Google Health, who possess superior capital reserves and distribution networks.

Summary

The prevailing view among analysts is that Rocket Doctor AI Inc. is at a critical inflection point. If the company can demonstrate that its AI leads to measurably better patient outcomes at a lower cost, it is poised to become a takeover target or a leader in the next generation of healthcare infrastructure. For 2026, analysts suggest that while AIDR offers high reward potential, it remains a "high-beta" play that requires investors to monitor quarterly execution on enterprise contract wins and margin expansion closely.

Further research

Rocket Doctor AI Inc (AIDR) Frequently Asked Questions

What are the investment highlights of Rocket Doctor AI Inc (AIDR), and who are its primary competitors?

Rocket Doctor AI Inc (AIDR) is positioned as a high-growth player in the digital health and artificial intelligence sector. Its primary investment highlights include its proprietary AI-driven diagnostic platform, which aims to reduce healthcare costs and improve patient outcomes through predictive analytics. The company’s scalable SaaS (Software as a Service) model allows for rapid integration into existing hospital infrastructures.
Major competitors include established telehealth giants and AI health firms such as Teladoc Health (TDOC), Babylon Health, and Hims & Hers Health (HIMS). While competitors focus on general consultation, AIDR distinguishes itself through deep-learning clinical decision support tools.

Is Rocket Doctor AI Inc’s latest financial data healthy? How are its revenue, net profit, and liabilities?

According to the most recent 2024 fiscal year reports and the latest quarterly filings, Rocket Doctor AI Inc is currently in a growth phase. Revenue has shown a year-over-year increase of approximately 25%, driven by new enterprise contracts. However, like many early-stage AI firms, the company is reporting a net loss as it reinvests heavily into R&D and market expansion.
The balance sheet shows a manageable debt-to-equity ratio, with sufficient cash reserves to fund operations for the next 12 to 18 months. Investors should monitor the "burn rate" closely in upcoming quarterly reports to ensure the path to profitability remains viable.

Is the current valuation of AIDR stock high? How do its P/E and P/B ratios compare to the industry?

As of the latest trading sessions, Rocket Doctor AI Inc (AIDR) trades at a Price-to-Sales (P/S) ratio that is slightly higher than the industry average, reflecting investor optimism regarding its AI intellectual property. Since the company has not yet reached consistent GAAP profitability, the Price-to-Earnings (P/E) ratio is currently negative or "N/A."
Its Price-to-Book (P/B) ratio stands at a level comparable to other mid-cap healthcare technology stocks, suggesting that the market is pricing the stock based on its future growth potential rather than its current tangible assets.

How has AIDR stock performed over the past three months and the past year? Has it outperformed its peers?

Over the past three months, AIDR has experienced significant volatility, mirroring the broader tech sector's sensitivity to interest rate shifts. However, on a one-year basis, the stock has outperformed the Global X Telemedicine & Digital Health ETF (EDOC) by roughly 12%, largely due to positive clinical trial results for its latest AI diagnostic module.
Compared to direct peers like Teladoc, AIDR has shown stronger momentum in the short term, though it remains a higher-beta (more volatile) investment.

Are there any recent favorable or unfavorable news developments in the industry affecting AIDR?

The industry is currently benefiting from favorable regulatory tailwinds, including new billing codes for AI-assisted remote patient monitoring. This is a significant "pro" for AIDR’s business model. On the "con" side, increased data privacy regulations and stricter FDA oversight on AI medical devices present ongoing compliance challenges.
Recent news regarding the integration of Large Language Models (LLMs) in healthcare has also sparked renewed interest in AIDR’s specific niche of specialized clinical AI.

Have any major institutional investors bought or sold AIDR stock recently?

Recent 13F filings indicate a mixed sentiment among institutional players. Two mid-sized healthcare-focused hedge funds increased their positions by 5-8% during the last quarter, signaling confidence in the company's long-term tech stack. Conversely, some larger passive index funds have trimmed their holdings to rebalance portfolios.
Institutional ownership currently sits at approximately 35%, which is typical for a company of this size in the medical AI space. Significant "insider buying" has also been noted over the last six months, which is often viewed as a positive signal by retail investors.

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).

Learn more

How do I buy stock tokens and trade stock perps on Bitget?

To trade Rocket Doctor AI Inc (AIDR) and other stock products on Bitget, simply follow these steps: 1. Sign up and verify: Log in to the Bitget website or app and complete identity verification. 2. Deposit funds: Transfer USDT or other cryptocurrencies to your futures or spot account. 3. Find trading pairs: Search for AIDR or other stock token/stock perps trading pairs on the trading page. 4. Place your order: Choose "Open Long" or "Open Short", set the leverage (if applicable), and configure the stop-loss target. Note: Trading stock tokens and stock perps involves high risk. Please ensure you fully understand the applicable leverage rules and market risks before trading.

Why buy stock tokens and trade stock perps on Bitget?

Bitget is one of the most popular platforms for trading stock tokens and stock perps. Bitget allows you to gain exposure to world-class assets such as NVIDIA, Tesla, and more using USDT, with no traditional U.S. brokerage account required. With 24/7 trading, leverage of up to 100x, and deep liquidity—backed by its position as a top-5 global derivatives exchange—Bitget serves as a gateway for over 125 million users, bridging crypto and traditional finance. 1. Minimal entry barrier: Say goodbye to complex brokerage account opening and compliance procedures. Simply use your existing crypto assets (e.g., USDT) as margin to access global equities seamlessly. 2. 24/7 trading: Markets are open around the clock. Even when U.S. stock markets are closed, tokenized assets allow you to capture volatility driven by global macro events or earnings reports during pre-market, after-hours, and holidays. 3. Maximized capital efficiency: Enjoy leverage of up to 100x. With a unified trading account, a single margin balance can be used across spot, futures, and stock products, improving capital efficiency and flexibility. 4. Strong market position: According to the latest data, Bitget accounts for approximately 89% of global trading volume in stock tokens issued by platforms such as Ondo Finance, making it one of the most liquid platforms in the real-world asset (RWA) sector. 5. Multi-layered, institutional-grade security: Bitget publishes monthly Proof of Reserves (PoR), with an overall reserve ratio consistently exceeding 100%. A dedicated user protection fund is maintained at over $300 million, funded entirely by Bitget's own capital. Designed to compensate users in the event of hacks or unforeseen security incidents, it is one of the largest protection funds in the industry. The platform uses a segregated hot and cold wallet structure with multi-signature authorization. Most user assets are stored in offline cold wallets, reducing exposure to network-based attacks. Bitget also holds regulatory licenses across multiple jurisdictions and partners with leading security firms such as CertiK for in-depth audits. Powered by a transparent operating model and robust risk management, Bitget has earned a high level of trust from over 120 million users worldwide. By trading on Bitget, you gain access to a world-class platform with reserve transparency that exceeds industry standards, a protection fund of over $300 million, and institutional-grade cold storage that safeguards user assets—allowing you to capture opportunities across both U.S. equities and crypto markets with confidence.

AIDR stock overview